Chip stocks fall with Nvidia after data center rev disappointment
Phillip Frost, CEO and Chairman of OPKO Health Inc. (NASDAQ:OPK), has acquired a significant amount of the company's common stock. According to a recent SEC filing, Frost purchased 125,000 shares on April 10, 2025, at a weighted average price of approximately $1.3577 per share, resulting in a total transaction value of $169,712. The purchase comes as InvestingPro data shows the stock trading near its Fair Value, with shares down 5% in the past week despite maintaining a healthy current ratio of 3.43x.
The shares were acquired indirectly through Frost Gamma Investments Trust, where Frost serves as trustee. Following this transaction, Frost's indirect ownership in OPKO Health stands at 214,001,448 shares. Additionally, he holds 3,568,951 shares directly and 30,127,177 shares indirectly through other entities. InvestingPro analysis reveals management's continued share purchases as a positive signal, with 8 additional exclusive ProTips available for subscribers looking to make informed investment decisions about OPK's $910M market cap healthcare company.
In other recent news, Opko Health reported its fourth-quarter 2024 earnings, surpassing expectations with an earnings per share (EPS) of $0.01, against a forecasted loss of $0.08. However, the company's revenue of $103.1 million fell short of the anticipated $156.35 million. In a strategic move, Opko Health announced a significant transaction with Labcorp, selling laboratory testing businesses for $192.5 million, with an additional earn-out of up to $32.5 million. Additionally, Opko Health expanded its stock repurchase program to $200 million, reflecting confidence in its business strategy. H.C. Wainwright maintained a Buy rating on Opko Health, with a price target of $3.00, highlighting the company's proactive measures to increase shareholder value. Opko Health also entered into a collaboration with Entera Bio (NASDAQ:ENTX) to develop an oral treatment for obesity, holding a 60% ownership interest in the partnership. The companies plan to submit an Investigational New Drug application to the FDA later this year. Despite the revenue miss, Opko Health remains optimistic about its future, projecting total revenue between $675 million and $700 million for 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.